Author

David T. Rubin 1

1 University of Chicago Medicine,Inflammatory Bowel Disease Center,Chicago,United States of America

BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS

Gary R. Lichtenstein, Andrew Tinsley, Xavier Roblin, Tadakazu Hisamatsu, Camille Vong, Shinichi Tsuchiwata, Konstantinos Tsilkos, Haiying Zhang, Arnab Mukherjee, Chinyu Su, David T. Rubin

COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin

COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin, Ajibade O Ashaye, Younan Zhang, yingxin xu, Kyle Fahrbach, Lea Ann Chen, Alireza Manuchehri, Cem Kayhan, John Woolcott, Joseph C. Cappelleri

EFFECT OF REMISSION STATUS ON THE ABILITY TO MAINTAIN OR ACHIEVE CLINICAL AND ENDOSCOPIC REMISSION AFTER 12-MONTH MAINTENANCE TREATMENT WITH MMX MESALAZINE IN ADULTS WITH ULCERATIVE COLITIS

Susi Inglis, Elizabeth Magee, Paul Streck, Dory Solomon, David T. Rubin, Geert R. D'Haens

EFFICACY OF TOFACITINIB AND BIOLOGICS AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin, Ajibade O Ashaye, Younan Zhang, Kyle Fahrbach, Andreas Freitag, Cem Kayhan, Christoph Lohan, Joseph C. Cappelleri, Marco DiBonaventura

EFFICACY OF TOFACITINIB AND BIOLOGICS AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin

EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Severine Vermeire, Hu Renwei, Remo Panaccione, Satoshi Tanida, Xavier Hebuterne, Ilo Dapo, Zhou Wen, Zhou Qing, Silvio Danese, Michael Weinreich, David T. Rubin

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan, Julian Panés, Aaron Duvall, Yoram Bouhnik, Graham Radford-Smith, Peter D.R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, David T. Rubin

ETROLIZUMAB INDUCTION THERAPY IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: RESULTS FROM THE HICKORY OPEN-LABEL INDUCTION (OLI) TRIAL

Laurent Peyrin-Biroulet, David T. Rubin, Brian G. Feagan, Young S. Oh, Udaysankar Arulmani, Helen Tyrrell, Romeo Maciuca, Sarah Williams, Swati Tole, James Thommes

ETROLIZUMAB TREATMENT IMPROVES HISTOLOGICAL ACTIVITY AS ASSESSED BY BOTH THE ROBARTS HISTOPATHOLOGY AND NANCY HISTOLOGICAL INDICES

Laurent Peyrin-Biroulet, Brian G. Feagan, Gert De Hertogh, David T. Rubin, Romeo Maciuca, Jacqueline McBride, Udaysankar Arulmani, Alexis Scherl

Item 1 - 10 / 30
1
2 3